Argenx stock edges lower as Jefferies sticks with Buy rating

Published on 09/16/2026 at 14:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock closed at USD 1,001.50 on Nasdaq on September 15, 2026, down 0.02 percent from the prior session. Jefferies reaffirmed its Buy rating and USD 1,215 price target, keeping upside of 17.6 percent in view for investors.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx stock (ISIN NL0010832176) closed at USD 1,001.50 on Nasdaq on September 15, 2026, a marginal decline of 0.02 percent from the previous session according to a recent market overview from ad hoc news on September 16, 2026.

Jefferies maintains Buy and USD 1,215 target

As ad hoc news reports, Jefferies has reiterated its Buy rating on Argenx stock and kept its price target at USD 1,215 as of September 16, 2026, implying upside of 17.6 percent versus the Nasdaq close of USD 1,001.50 on September 15, 2026.

This quantified gap between the current price and the target suggests that Jefferies still sees meaningful potential in the biotech group despite the modest share-price pullback in the latest session, an interpretation investors will weigh against the broader volatility in healthcare names.

Trading range, Brussels quote and market capitalization

According to closing data cited by ad hoc news, Argenx traded in a relatively tight intraday range between USD 986.26 and USD 1,013.84 on Nasdaq on September 15, 2026, leaving the closing price of USD 1,001.50 comfortably inside that band.

In parallel, the company is also listed in Brussels under the ticker ARGX, where the shares recently changed hands at EUR 854.80 with a day range of EUR 849.00 to EUR 858.80 on September 16, 2026 based on live quote data shown by Investing.com.

On the valuation side, Argenx carries a market capitalization of USD 60.92 billion as of September 2026, placing it around the 409th position globally by market value according to a ranking compiled by CompaniesMarketCap, which also notes that the 2026 market cap level is up 15.79 percent versus the prior year.

Fund positioning highlights growth profile

Beyond the day-to-day moves, Argenx features in institutional growth portfolios as a healthcare holding with a meaningful weight. In its second-quarter 2026 shareholder letter, Baron International Growth Fund highlighted Argenx SE as one of the healthcare positions that contributed positively to relative performance, with the stock representing about 3.5 percent of fund assets at the end of the quarter. This fund-level exposure underscores how Argenx has become a core growth name for some active managers, which can amplify both upside and downside moves as sentiment shifts around biotech valuations.

Stock level and investor takeaway

With Argenx stock last closing at USD 1,001.50 on Nasdaq on September 15, 2026 and Jefferies maintaining a Buy rating and USD 1,215 target on September 16, 2026, the shares currently trade roughly one sixth below that analyst objective while the company commands a market capitalization of about USD 60.92 billion as of September 2026.